Table 1.

LV functional parameters in control and doxorubicin-treated WT and Nox2−/− mice

WT controlWT DOXNox2−/− controlNox2−/− DOX
Echocardiography data
    n15111617
    Heart rate (bpm)511 ± 7518 ± 16491 ± 16503 ± 14
    LVEDD (mm)4.12 ± 0.044.12 ± 0.074.24 ± 0.064.25 ± 0.06
    LVESD (mm)2.73 ± 0.073.07 ± 0.08*2.77 ± 0.092.86 ± 0.15
    FS (%)34.4 ± 1.225.7 ± 1.034.8 ± 1.429.5 ± 1.4*
Pressure-volume data
    n1010810
    MABP (mmHg)79.5 ± 3.378.2 ± 2.779.6 ± 2.377.6 ± 3.0
    LVESP (mmHg)105 ± 3.398 ± 2.1100 ± 2.5100 ± 2.8
    LVEDP (mmHg)6.6 ± 1.015.4 ± 2.4§6.9 ± 1.54.9 ± 1.0
    LVdP/dtmax (mmHg s−1)9,676 ± 3866,114 ± 5209,481 ± 4758,965 ± 475
    LVdP/dtmin (mmHg s−1)−8,218 ± 337−5,198 ± 527−8,600 ± 472−8,379 ± 416
    τ (ms)6.0 ± 0.310.3 ± 0.66.3 ± 0.55.7 ± 0.5
    LVESV (μL)33.5 ± 3.363.2 ± 9.0§32.8 ± 5.438.6 ± 3.8
    LVEDV (μL)70.3 ± 7.177.6 ± 8.869.0 ± 5.569.0 ± 6.0
    Stroke volume (μL)43.2 ± 5.324.1 ± 3.2§43.1 ± 4.338.3 ± 3.2
    Ejection fraction (%)56.5 ± 3.528.5 ± 2.358.9 ± 4.952.6 ± 2.5
    SW (mmHg.μL g−1)37,964 ± 5,29116,658 ± 3,44840,359 ± 3,28629,074 ± 2,327
    ESPVR2.43 ± 0.421.17 ± 0.38*2.64 ± 0.292.31 ± 0.20
    EDPVR0.040 ± 0.0110.114 ± 0.0120.041 ± 0.0080.051 ± 0.009

NOTE: Mean ± SEM.

Abbreviations: DOX, doxorubicin; FS, fractional shortening; LVEDV, LV end-diastolic volume; LVESP, LV end-systolic pressure; LVESV, LV end-systolic volume; MABP, mean arterial blood pressure; SW, stroke work.

  • *P < 0.05 versus control.

  • P < 0.001 versus control.

  • P < 0.05, Nox2−/− doxorubicin versus WT doxorubicin.

  • §P < 0.01 versus control.

  • P < 0.001, Nox2−/− doxorubicin versus WT doxorubicin.